EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD
Empagliflozin's efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.
Medscape Medical News
source https://www.medscape.com/viewarticle/984439?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/984439?src=rss
Comments
Post a Comment